Table 4 Drug resistance-conferring mutation profiles among TB patients with second line drug-resistance
Drug (N = 68) | Resistance conferring mutation profile (s) | n (%; 95% CI) |
|---|---|---|
FQ (Pre-XDR) | ||
gyrA (A90V) | 11 (16.2; 8.4–27.1) | |
gyrA S91P | 2 (2.9; 0.4–10.2) | |
gyrA (D94A) | 1 (1.5; 0.0–7.9) | |
gyrA (D94N/Y) | 8 (11.8; 5.2–21.8) | |
gyrA (D94G) | 13 (19.1; 10.6–30.5) | |
gyrA (A90V, D94G) | 3 (4.4; 0.9–12.4) | |
gyrA (A90V, D94N/Y, D94G) | 4 (5.9; 1.6–14.4) | |
IA | ||
rrs (A1401G) | 6 (8.8; 3.3–18.2) | |
rrs (G1484T) | 6 (8.8; 3.3–18.2) | |
FQ & IA | ||
gyrA (A90V)/rrs (A1401G) | 7 (10.3; 4.2–20.1) | |
gyrA (D94G)/rrs (A1401G) | 1 (1.5; 0.0–7.9) | |
gyrA (D94G)/rrs (A1401G) | 3 (4.4; 0.9–12.4) | |
gyrA (S91P, D94A/rrs (A1401G) | 1 (1.5; 0.0–7.9) | |
gyrA (D94A, D94G)/rrs (A1401G) | 1 (1.5; 0.0–7.9) | |
gyrA (D94H, D94G)/gyrB (E540D)/rrs (A1401G)/eis (C14T) | 1 (1.5; 0.0–7.9) | |